-
Sorafenib has been approved by the FDA forthe treatment of inoperable hepatocellular cancer. It is an oral multikinase inhibitor that was previously approved for advanced renal cell carcinoma. It is manufactured by Bayer HealthCare AG in Germany and marketed by Bayer Pharmaceuticals Corporation as Nexavar.
-
Incidentalomas:It's All In Your Head, Skin Cancer Screening: Our Patients Want It!, and Bell's Palsy: Steroids, Acyclovir, Both, or Neither?
-
Many nursing home patients are admitted with prescriptions for proton pump inhibitors or H2-receptor antagonists without any obvious indication.
-
Treatment of systolic hypertension in older patients with systolic blood pressure of at least 160 mm Hg is supported by strong evidence. The evidence to support treatment of patients to the level of 140 mm Hg or those with baseline SBP of 140 to 159 mm Hg is less strong; thus, these treatment decisions should be more sensitive to patient preferences and tolerance of therapy.
-
Use of ß-blockers is associated with reduced risk of
fracture. The magnitude of reduction is similar to that seen with use of thiazides.
-
Toenail Chromium in Men With Diabetes and Cardiovascular Disease; Combination of Fenofibrate and Rosiglitazone and HDL Cholesterol; Outcomes for Patients with Diet-Controlled Diabetes
-
The FDA has approved a combination of 2 antiretrovirals, abacavir and lamivudine for the treatment of HIV-1 infections.
-
A calcium score < 100 eliminates the need for MPS, but patients with a negative MPS often have coronary calcium. These findings imply a potential role for applying CAC screening after MPS among patients manifesting normal MPS.
-
A retrospective study of 24,112 patients with coronary heart disease showed increased 30-day mortality in patients who received one or more blood transfusions for anemia compared to comparable patients not transfused.
-
The NIH has halted the estrogen-alone wing of the Womens Health Initiative a year before its scheduled end.
